A targeted ferritin-microplasmin based thrombolytic nanocage selectively dissolves blood clots
J Seo, TA Al-Hilal, JG Jee, YL Kim, HJ Kim… - … , Biology and Medicine, 2018 - Elsevier
The use of thrombolytic therapies is limited by an increased risk of systemic hemorrhage due
to lysis of hemostatic clots. We sought to develop a plasmin-based thrombolytic nanocage …
to lysis of hemostatic clots. We sought to develop a plasmin-based thrombolytic nanocage …
A targeted ferritin-microplasmin based thrombolytic nanocage selectively dissolves blood clots
J Seo, TA Al-Hilal, JG Jee, YL Kim… - NANOMEDICINE …, 2018 - scholar.korea.ac.kr
The use of thrombolytic therapies is limited by an increased risk of systemic hemorrhage due
to lysis of hemostatic clots. We sought to develop a plasmin-based thrombolytic nanocage …
to lysis of hemostatic clots. We sought to develop a plasmin-based thrombolytic nanocage …
A targeted ferritin-microplasmin based thrombolytic nanocage selectively dissolves blood clots.
J Seo, TA Al-Hilal, JG Jee, YL Kim, HJ Kim… - Nanomedicine …, 2018 - europepmc.org
The use of thrombolytic therapies is limited by an increased risk of systemic hemorrhage due
to lysis of hemostatic clots. We sought to develop a plasmin-based thrombolytic nanocage …
to lysis of hemostatic clots. We sought to develop a plasmin-based thrombolytic nanocage …
[PDF][PDF] A targeted ferritin-microplasmin based thrombolytic nanocage selectively dissolves blood clots
J Seo, TA Al-Hilal, JG Jee, YL Kim, HJ Kim… - … Biology, and Medicine, 2018 - academia.edu
The use of thrombolytic therapies is limited by an increased risk of systemic hemorrhage due
to lysis of hemostatic clots. We sought to develop a plasmin-based thrombolytic nanocage …
to lysis of hemostatic clots. We sought to develop a plasmin-based thrombolytic nanocage …
A targeted ferritin-microplasmin based thrombolytic nanocage selectively dissolves blood clots
J Seo, TA Al-Hilal, JG Jee, YL Kim… - Nanomedicine …, 2018 - pubmed.ncbi.nlm.nih.gov
The use of thrombolytic therapies is limited by an increased risk of systemic hemorrhage due
to lysis of hemostatic clots. We sought to develop a plasmin-based thrombolytic nanocage …
to lysis of hemostatic clots. We sought to develop a plasmin-based thrombolytic nanocage …
A targeted ferritin-microplasmin based thrombolytic nanocage selectively dissolves blood clots
J Seo, TA Al-Hilal, JG Jee, YL Kim, HJ Kim… - Nanomedicine …, 2018 - pure.korea.ac.kr
The use of thrombolytic therapies is limited by an increased risk of systemic hemorrhage due
to lysis of hemostatic clots. We sought to develop a plasmin-based thrombolytic nanocage …
to lysis of hemostatic clots. We sought to develop a plasmin-based thrombolytic nanocage …